Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLK4 | O00444 | 1/20 | 1.00 |
| ▸ | CHEK1 | O14757 | 1/20 | 1.00 |
| ▸ | AURKA | O14965 | 1/20 | 1.00 |
| ▸ | DAPK3 | O43293 | 1/20 | 1.00 |
| ▸ | MAP4K4 | O95819 | 1/20 | 1.00 |
| ▸ | CSF1R | P07333 | 1/20 | 1.00 |
| ▸ | RET | P07949 | 1/20 | 1.00 |
| ▸ | FGFR1 | P11362 | 1/20 | 1.00 |
| ▸ | PDGFRA | P16234 | 1/20 | 1.00 |
| ▸ | LTK | P29376 | 1/20 | 1.00 |
| ▸ | KDR | P35968 | 1/20 | 1.00 |
| ▸ | MAP2K2 | P36507 | 1/20 | 1.00 |
| ▸ | FLT3 | P36888 | 1/20 | 1.00 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 1.00 |
| ▸ | PRKX | P51817 | 1/20 | 1.00 |
| ▸ | CDK5 | Q00535 | 1/20 | 1.00 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 1.00 |
| ▸ | MST1R | Q04912 | 1/20 | 1.00 |
| ▸ | PTK2 | Q05397 | 1/20 | 1.00 |
| ▸ | BTK | Q06187 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29696521 | 1.00 | PLK4 (1.00) | PLK4CHEK1AURKADAPK3MAP4K4 | |
| Oxalic Acid SCHEMBL28217953 | 0.95 | PLK4 (0.90) | PLK4CHEK1AURKADAPK3MAP4K4 | |
| Fumaric Acid SCHEMBL16827089 | 0.91 | PLK4 (0.82) | PLK4CHEK1AURKADAPK3MAP4K4 | |
| Fumaric Acid SCHEMBL16827083 | 0.91 | PLK4 (0.82) | PLK4CHEK1AURKADAPK3MAP4K4 | |
| Trifluoroacetic Acid SCHEMBL2264262 | 0.89 | PLK4 (0.80) | PLK4CHEK1AURKADAPK3MAP4K4 | |
| SCHEMBL29520722 | 0.84 | PLK4 (0.72) | PLK4CHEK1AURKADAPK3MAP4K4 | |
| SCHEMBL259689 | 0.84 | PLK4 (0.72) | PLK4CHEK1AURKADAPK3MAP4K4 | |
| SCHEMBL3386425 | 0.82 | PLK4 (0.70) | PLK4CHEK1AURKADAPK3MAP4K4 | |
| SCHEMBL20616534 | 0.82 | PLK4 (0.70) | PLK4CHEK1AURKADAPK3MAP4K4 | |
| Water SCHEMBL31216383 | 0.82 | PLK4 (0.67) | PLK4CHEK1AURKADAPK3MAP4K4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 109 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120004864-A | Bicyclic compounds, compositions comprising the same and uses thereof | 贝达药业股份有限公司 | 2025-05-16 | — | — | CN | claimed |
| WO-2024083705-A1 | FUROINDAZOLE DERIVATIVES FOR THE TREATMENT OF PAIN | BAYER AKTIENGESELLSCHAFT (DE) | 2024-04-25 | — | — | WO | claimed |
| EP-3472149-B1 | HETEROCYCLIC PROLINAMIDE DERIVATIVES | Orion Ophthalmology LLC (US) | 2023-08-30 | — | — | EP | claimed |
| WO-2023143236-A1 | 2H-INDAZOLE-7-FORMAMIDE COMPOUND, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION, AND APPLICATION | 中国药科大学 | 2023-08-03 | — | — | WO | claimed |
| EP-4136069-A1 | HYPOXIA INDUCIBLE FACTOR-2(ALPHA) INHIBITORS AND THEIR USE IN THE TREATMENT OF DISEASES | Nikang Therapeutics, Inc. (US) | 2023-02-22 | — | — | EP | claimed |
| CN-113637002-B | Preparation method of Nilaparib | 天津太平洋化学制药有限公司 | 2022-09-30 | — | — | CN | claimed |
| WO-2019164847-A1 | INDAZOLE COMPOUNDS AND USES THEREOF | INCYTE CORPORATION (US) | 2019-08-29 | — | — | WO | claimed |
| CN-110177781-A | Bruton's tyrosine kinase inhibitor | BIOCAD股份有限公司 | 2019-08-27 | — | — | CN | claimed |
| CN-109563033-A | Aliphatic Prolinamide derivatives | 奥瑞恩眼科有限责任公司 | 2019-04-02 | — | — | CN | claimed |
| CN-109476637-A | heterocyclic Prolinamide derivatives | 奥瑞恩眼科有限责任公司 | 2019-03-15 | — | — | CN | claimed |
| CN-105873920-B | As 5-HT4The indazole compound of receptor stimulating agent | 苏文生命科学有限公司 | 2018-06-08 | — | — | CN | claimed |
| CN-106456582-A | TrkA kinase inhibitors, compositions and methods thereof | 默沙东公司 | 2017-02-22 | — | — | CN | claimed |
| CN-106432187-A | Chiral resolution method of 2-[4-(-3-piperidyl)phenyl]-2H-indazole-7-formamide | 青岛云天生物技术有限公司 | 2017-02-22 | — | — | CN | claimed |
| CN-106432188-A | Preparation method of anti-cancer drug 2-[4-((3S)-3-Piperidinyl) phenyl]-2H-Indazole-7-Formamide | 青岛辰达生物科技有限公司 | 2017-02-22 | — | — | CN | claimed |
| EP-3097092-A1 | FUSED PYRIMIDINES AS INHIBITORS OF p97 COMPLEX | Cleave Biosciences, Inc. (US) | 2016-11-30 | — | — | EP | claimed |
| WO-2015109285-A1 | FUSED PYRIMIDINES AS INHIBITORS OF p97 COMPLEX | CLEAVE BIOSCIENCES, INC. (US) | 2015-07-23 | — | — | WO | claimed |
| WO-2015051766-A1 | AMIDS SUBSTITUTED INDAZOLE DERIVATIVEES AS PLOY (ADP-RIBOSE) POLYMERASE INHIBITORS | BETTA PHARMACEUTICALS CO., LTD (CN) | 2015-04-16 | — | — | WO | claimed |
| CN-101578279-A | Amide substituted indazoles as poly (ADP ribose) polymerase (PARP) inhibitors | ANGELETTI P IST RICHERCHE BIO (IT) | 2009-11-11 | — | — | CN | claimed |
| CN-101541757-A | Pyrazolines as Mineralocorticoid Receptor Antagonists | PFIZER PROD INC (US) | 2009-09-23 | — | — | CN | claimed |
| WO-2026107377-A1 | PHARMACOLOGICAL RE-ACTIVATION OF MUTANT PVHL | KARANICOLAS JOHN (US) | 2026-05-21 | — | — | WO | disclosed |
| US-12570666-B2 | Furoindazole derivatives | BAYER AKTIENGESELLSCHAFT (DE) | 2026-03-10 | — | — | US | disclosed |
| US-20250270212-A1 | CHIMERIC COMPOUNDS USEFUL IN TREATING DISEASES | PADARN THERAPEUTICS INC (US) | 2025-08-28 | — | — | US | disclosed |
| CN-120004864-A | Bicyclic compounds, compositions comprising the same and uses thereof | 贝达药业股份有限公司 | 2025-05-16 | — | — | CN | disclosed |
| WO-2025045837-A1 | PESTICIDALLY ACTIVE INDAZOLE COMPOUNDS | SYNGENTA CROP PROTECTION AG (CH) | 2025-03-06 | — | — | WO | disclosed |
| CN-119431323-A | Heterobicyclic amides as CD38 inhibitors | 贝林格尔·英格海姆国际有限公司 | 2025-02-14 | — | — | CN | disclosed |
| US-12221436-B2 | Anthranilamides, their use as insecticide and processes for preparing the same | PI INDUSTRIES LTD. (IN) | 2025-02-11 | — | — | US | disclosed |
| US-20240417407-A1 | FUROINDAZOLE DERIVATIVES AS GPR84 ANTAGONISTS | BAYER AKTIENGESELLSCHAFT (DE) | 2024-12-19 | — | — | US | disclosed |
| US-20240383905-A1 | FGFR INHIBITORS AND METHODS OF USE THEREOF | 3H PHARMACEUTICALS CO., LTD. (CN) | 2024-11-21 | — | — | US | disclosed |
| CN-114423753-B | Heterobicyclic amides as CD38 inhibitors | 里邦医疗公司 | 2024-09-17 | — | — | CN | disclosed |
| WO-2024182778-A1 | COMPOUNDS AND METHODS FOR MODULATING SPLICING | REMIX THERAPEUTICS INC. (US) | 2024-09-06 | — | — | WO | disclosed |
| US-20240239804-A1 | FUROINDAZOLE DERIVATIVES AS ANTAGONISTS OR INHIBITORS OF GPR84 | BAYER AKTIENGESELLSCHAFT (DE) | 2024-07-18 | — | — | US | disclosed |
| EP-4395892-A1 | COMPOUNDS AND METHODS FOR MODULATING SPLICING | Remix Therapeutics Inc. (US) | 2024-07-10 | — | — | EP | disclosed |
| CN-116535395-B | 2H-indazole-7-carboxamide compounds, preparation method, pharmaceutical composition and application | 中国药科大学 | 2024-07-09 | — | — | CN | disclosed |
| CN-115135656-B | Furanoindazole derivatives | 拜耳公司 | 2024-06-14 | — | — | CN | disclosed |
| EP-4376616-A1 | METHOD FOR CONTROLLING DIAMIDE RESISTANT PESTS & COMPOUNDS THEREFOR | Syngenta Crop Protection AG (CH) | 2024-06-05 | — | — | EP | disclosed |
| CN-117715523-A | Methods for controlling diamide-resistant pests and compounds thereof | 先正达农作物保护股份公司 | 2024-03-15 | — | — | CN | disclosed |
| CN-117651701-A | Novel substituted bicyclic aza heterocycles as SOS1 inhibitors | 唯久生物技术(苏州)有限公司 | 2024-03-05 | — | — | CN | disclosed |
| CN-117430587-A | 2H-indazole-7-carboxamide PARP7 inhibitors and application thereof | 中国药科大学 | 2024-01-23 | — | — | CN | disclosed |
| CN-116916914-A | SOS1 inhibitors and uses thereof | 锐新医药公司 | 2023-10-20 | — | — | CN | disclosed |
| WO-2023143236-A1 | 2H-INDAZOLE-7-FORMAMIDE COMPOUND, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION, AND APPLICATION | 中国药科大学 | 2023-08-03 | — | — | WO | disclosed |
| CN-116348453-A | Heteroaromatic carboxamide compounds and uses thereof | 烨辉医药科技(上海)有限公司 | 2023-06-27 | — | — | CN | disclosed |
| US-11649255-B2 | Indazoles as hematopoietic progenitor kinase 1 (HPK1) inhibitors and methods using same | 1ST Biotherapeutics, Inc. (KR) | 2023-05-16 | — | — | US | disclosed |
| US-20230112499-A1 | FUROINDAZOLE DERIVATIVES | BAYER AKTIENGESELLSCHAFT (DE) | 2023-04-13 | — | — | US | disclosed |
| WO-2023006634-A1 | METHOD FOR CONTROLLING DIAMIDE RESISTANT PESTS & COMPOUNDS THEREFOR | SYNGENTA CROP PROTECTION AG (CH) | 2023-02-02 | — | — | WO | disclosed |
| US-11535621-B2 | Heterobicyclic amides as inhibitors of CD38 | RIBON THERAPEUTICS, INC. (US) | 2022-12-27 | — | — | US | disclosed |
| WO-2022257961-A1 | BENZOHETEROCYCLIC COMPOUND FOR TREATING EP2 AND EP4 RECEPTOR-MEDIATED DISEASES | 武汉人福创新药物研发中心有限公司 | 2022-12-15 | — | — | WO | disclosed |
| CN-115448882-A | Benzoheterocyclic compounds useful for the treatment of EP2, EP4 receptor mediated diseases | 武汉人福创新药物研发中心有限公司 | 2022-12-09 | — | — | CN | disclosed |
| WO-2022237676-A1 | PREPARATION AND APPLICATION OF SHP2 PHOSPHATASE INHIBITOR | 药雅科技(上海)有限公司 | 2022-11-17 | — | — | WO | disclosed |
| WO-2022228302-A1 | HETEROAROMATIC CARBOXAMIDE COMPOUNDS AND ITS USE | BIONOVA PHARMACEUTICALS (SHANGHAI) LIMITED (CN) | 2022-11-03 | — | — | WO | disclosed |
| CN-113637002-B | Preparation method of Nilaparib | 天津太平洋化学制药有限公司 | 2022-09-30 | — | — | CN | disclosed |
| CN-113637002-B | Preparation method of Nilaparib | 天津太平洋化学制药有限公司 | 2022-09-30 | — | — | CN | disclosed |
| US-20220267306-A1 | HETEROCYCLIC PROLINAMIDE DERIVATIVES | Orion Ophthalmology LLC (US) | 2022-08-25 | — | — | US | disclosed |
| US-11377439-B2 | Heterocyclic prolinamide derivatives | Orion Ophthalmology LLC (US) | 2022-07-05 | — | — | US | disclosed |
| CN-114685453-A | Heterocyclic prolinamide derivatives | 奥瑞恩眼科有限责任公司 | 2022-07-01 | — | — | CN | disclosed |
| CN-114423753-A | Heterobicyclic amides as CD38 inhibitors | 里邦医疗公司 | 2022-04-29 | — | — | CN | disclosed |
| US-20220098193-A1 | INDAZOLES AS HEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) INHIBITORS AND METHODS USING SAME | 1ST Biotherapeutics, Inc. | 2022-03-31 | — | — | US | disclosed |
| US-20210363134-A1 | NOVEL ANTHRANILAMIDES, THEIR USE AS INSECTICIDE AND PROCESSES FOR PREPARING THE SAME | PI INDUSTRIES LTD. (IN) | 2021-11-25 | — | — | US | disclosed |
| US-10815214-B2 | Regioselective N-2 arylation of indazoles | MERCK SHARP & DOHME CORP. (US) | 2020-10-27 | — | — | US | disclosed |
| US-10435386-B2 | Regioselective N-2 arylation of indazoles | MERCK SHARP & DOHME CORP. (US) | 2019-10-08 | — | — | US | disclosed |
| CN-110300587-A | Deuterated (S) -2- (4- (piperidin-3-yl) phenyl) -2H-indazole-7-carboxamide | 康姆芘法思催化剂股份有限公司 | 2019-10-01 | — | — | CN | disclosed |
| CN-109640991-A | METHODS OF TREATING PROSTATE CANCER | 詹森药业有限公司 | 2019-04-16 | — | — | CN | disclosed |
| US-10174005-B2 | Fused pyrimidines as inhibitors of p97 complex | CLEAVE BIOSCIENCES, INC. (US) | 2019-01-08 | — | — | US | disclosed |
| CN-109081828-A | Poly- (ADP- ribose) polymerase inhibitors, Preparation method and use | 上海时莱生物技术有限公司 | 2018-12-25 | — | — | CN | disclosed |
| CN-108467386-A | 1,2,4- triazine -3- the amine derivants of thick heteroaryl substitution, preparation method and its application in medicine | 江苏恒瑞医药股份有限公司 | 2018-08-31 | — | — | CN | disclosed |
| CN-105873920-B | As 5-HT4The indazole compound of receptor stimulating agent | 苏文生命科学有限公司 | 2018-06-08 | — | — | CN | disclosed |
| US-20180044325-A1 | FUSED PYRIMIDINES AS INHIBITORS OF P97 COMPLEX | CLEAVE BIOSCIENCES, INC. | 2018-02-15 | — | — | US | disclosed |
| EP-2928473-B1 | REGIOSELECTIVE N-2 ARYLATION OF INDAZOLES | MERCK SHARP & DOHME (US) | 2017-06-28 | — | — | EP | disclosed |
| US-20170137403-A1 | REGIOSELECTIVE N-2 ARYLATION OF INDAZOLES | MERCK SHARP & DOHME CORP. (US) | 2017-05-18 | — | — | US | disclosed |
| US-9580407-B2 | Regioselective N-2 arylation of indazoles | MERCK SHARP & DOHME CORP. (US) | 2017-02-28 | — | — | US | disclosed |
| US-9580407-B2 | Regioselective N-2 arylation of indazoles | MERCK SHARP & DOHME CORP. (US) | 2017-02-28 | — | — | US | disclosed |
| CN-106432188-A | Preparation method of anti-cancer drug 2-[4-((3S)-3-Piperidinyl) phenyl]-2H-Indazole-7-Formamide | 青岛辰达生物科技有限公司 | 2017-02-22 | — | — | CN | disclosed |
| CN-106432187-A | Chiral resolution method of 2-[4-(-3-piperidyl)phenyl]-2H-indazole-7-formamide | 青岛云天生物技术有限公司 | 2017-02-22 | — | — | CN | disclosed |
| EP-3099675-A1 | INDAZOLE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS | Suven Life Sciences Limited (IN) | 2016-12-07 | — | — | EP | disclosed |
| EP-3097092-A1 | FUSED PYRIMIDINES AS INHIBITORS OF p97 COMPLEX | Cleave Biosciences, Inc. (US) | 2016-11-30 | — | — | EP | disclosed |
| CN-105873920-A | Indazole compounds as 5-HT4 receptor agonists | 苏文生命科学有限公司 | 2016-08-17 | — | — | CN | disclosed |
| EP-2007733-B1 | AMIDE SUBSTITUTED INDAZOLE AND BENZOTRIAZOLE DERIVATIVES AS POLY(ADP-RIBOSE)POLYMERASE (PARP) INHIBITORS | MSD ITALIA SRL (IT) | 2016-05-25 | — | — | EP | disclosed |
| US-20150299167-A1 | Regioselective N-2 Arylation of Indazoles | MERCK SHARP & DOHME CORP. (US) | 2015-10-22 | — | — | US | disclosed |
| US-20150299167-A1 | Regioselective N-2 Arylation of Indazoles | MERCK SHARP & DOHME CORP. (US) | 2015-10-22 | — | — | US | disclosed |
| EP-2928473-A1 | REGIOSELECTIVE N-2 ARYLATION OF INDAZOLES | Merck Sharp & Dohme Corp. (US) | 2015-10-14 | — | — | EP | disclosed |
| WO-2015109285-A1 | FUSED PYRIMIDINES AS INHIBITORS OF p97 COMPLEX | CLEAVE BIOSCIENCES, INC. (US) | 2015-07-23 | — | — | WO | disclosed |
| WO-2015092804-A1 | INDAZOLE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS | SUVEN LIFE SCIENCES LIMITED (IN) | 2015-06-25 | — | — | WO | disclosed |
| WO-2014088983-A1 | REGIOSELECTIVE N-2 ARYLATION OF INDAZOLES | MERCK SHARP & DOHME CORP. (US) | 2014-06-12 | — | — | WO | disclosed |
| CN-101378763-B | Trialkylsilylbenzylaminocarboxyindoles, indazoles and indolines and their use in treating CETP-mediated disorders | HOFFMANN LA ROCHE | 2013-05-22 | — | — | CN | disclosed |
| CN-101415686-B | Amide substituted indazole and benzotriazole derivatives as poly(ADP-ribose)polymerase (PARP) inhibitors | ANGELETTI P IST RICHERCHE BIO | 2013-03-13 | — | — | CN | disclosed |
| US-8071623-B2 | Anticancer, antiinflammatory, antitumor agents, diabetes, neurodegenerative diseases, retroviral infection, retinal damage or skin senescence and UV-induced skin damage; protecting against the toxicity of chemotherapy; 2-(4-Piperidin-3-ylphenyl)2H-indazole-7-carboxamide | INSTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA | 2011-12-06 | — | — | US | disclosed |
| US-20110201657-A1 | AMIDE SUBSTITUTED INDAZOLE AND BENZOTRIAZOLE DERIVATIVES AS POLY(ADP-RIBOSE)POLYMERASE (PARP) INHIBITORS | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) | 2011-08-18 | — | — | US | disclosed |
| CN-1993323-B | Indole, indazole or indoline derivatives | HOFFMANN LA ROCHE | 2011-04-20 | — | — | CN | disclosed |
| CN-101932572-A | Pharmaceutically acceptable salts of 2- {4- [ (3S) -piperidin-3-yl ] phenyl } -2H-indazole-7-carboxamide | MERCK & CO INC | 2010-12-29 | — | — | CN | disclosed |
| EP-1984002-B1 | TRIALKYLSILYLBENZYLAMINOCARBOXYINDOLES, INDAZOLES AND INDOLINES AND THEIR USE IN TREATING CETP-MEDIATED DISORDERS | HOFFMANN LA ROCHE (CH) | 2010-12-22 | — | — | EP | disclosed |
| CN-101578279-A | Amide substituted indazoles as poly (ADP ribose) polymerase (PARP) inhibitors | ANGELETTI P IST RICHERCHE BIO (IT) | 2009-11-11 | — | — | CN | disclosed |
| US-20090275619-A1 | Amide Substituted Indazole and Benzotriazole Derivatives as Poly(ADP-Ribose)Polymerase (PARP) Inhibitors | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) | 2009-11-05 | — | — | US | disclosed |
| US-20090275619-A1 | Amide Substituted Indazole and Benzotriazole Derivatives as Poly(ADP-Ribose)Polymerase (PARP) Inhibitors | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) | 2009-11-05 | — | — | US | disclosed |
| CN-101541757-A | Pyrazolines as Mineralocorticoid Receptor Antagonists | PFIZER PROD INC (US) | 2009-09-23 | — | — | CN | disclosed |
| US-7572823-B2 | Heteroaryl carboxamide compounds | HOFFMANN-LA ROCHE INC. (US) | 2009-08-11 | — | — | US | disclosed |
| EP-1758578-A4 | NOVEL INDAZOLE CARBOXAMIDES AND THEIR USE | SMITHKLINE BEECHAM CORP (US) | 2009-05-27 | — | — | EP | disclosed |
| CN-101415686-A | Amide substituted indazole and benzotriazole derivatives as poly(ADP-ribose)polymerase (PARP) inhibitors | ANGELETTI P IST RICHERCHE BIO (IT) | 2009-04-22 | — | — | CN | disclosed |
| CN-101378763-A | Trialkylsilylbenzylaminocarboxyindoles, indazoles and indolines and their use in treating CETP-mediated disorders | HOFFMANN LA ROCHE (CH) | 2009-03-04 | — | — | CN | disclosed |
| EP-2007733-A1 | AMIDE SUBSTITUTED INDAZOLE AND BENZOTRIAZOLE DERIVATIVES AS POLY(ADP-RIBOSE)POLYMERASE (PARP) INHIBITORS | Istituto di Richerche di Biologia Molecolare P. Angeletti S.p.A. (IT) | 2008-12-31 | — | — | EP | disclosed |
| US-20080167345-A1 | Anticancer, antiinflammatory, antitumor agents, diabetes, neurodegenerative diseases, retroviral infection, retinal damage or skin senescence and UV-induced skin damage; protecting against the toxicity of chemotherapy; 2-(4-Piperidin-3-ylphenyl)2H-indazole-7-carboxamide | MERCK SHARP & DOHME LLC | 2008-07-10 | — | — | US | disclosed |
| WO-2007113596-A1 | AMIDE SUBSTITUTED INDAZOLE AND BENZOTRIAZOLE DERIVATIVES AS POLY(ADP-RIBOSE)POLYMERASE (PARP) INHIBITORS | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) | 2007-10-11 | — | — | WO | disclosed |
| US-7259183-B2 | Indole, indazole and indoline derivatives as CETP inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2007-08-21 | — | — | US | disclosed |
| US-20070185182-A1 | Heteroaryl carboxamide compounds | HOFFMAN-LA ROCHE INC. | 2007-08-09 | — | — | US | disclosed |
| CN-101005836-A | Novel indazole carboxamides and their use | SMITHKLINE BEECHAM CORP (US) | 2007-07-25 | — | — | CN | disclosed |
| CN-1993323-A | Indole, indazole or indoline derivatives | HOFFMANN LA ROCHE (CH) | 2007-07-04 | — | — | CN | disclosed |
| EP-1758578-A2 | NOVEL INDAZOLE CARBOXAMIDES AND THEIR USE | Smithkline Beecham Corporation (US) | 2007-03-07 | — | — | EP | disclosed |
| US-20060030613-A1 | Indole, indazole and indoline derivatives as CETP inhibitors | F. HOFFMANN-LA ROCHE AG (CH) | 2006-02-09 | — | — | US | disclosed |
| WO-2006002434-A2 | NOVEL INDAZOLE CARBOXAMIDES AND THEIR USE | SMITHKLINE BEECHAM CORPORATION (US) | 2006-01-05 | — | — | WO | disclosed |
| EP-1543000-A1 | INDAZOLES, BENZOTHIAZOLES, AND BENZOISOTHIAZOLES, AND PREPARATION AND USES THEREOF | Memory Pharmaceuticals Corporation (US) | 2005-06-22 | — | — | EP | disclosed |
| WO-2004029050-A1 | INDAZOLES, BENZOTHIAZOLES, AND BENZOISOTHIAZOLES, AND PREPARATION AND USES THEREOF | MEMORY PHARMACEUTICALS CORPORATION (US) | 2004-04-08 | — | — | WO | disclosed |
| WO-2004029050-A1 | INDAZOLES, BENZOTHIAZOLES, AND BENZOISOTHIAZOLES, AND PREPARATION AND USES THEREOF | MEMORY PHARMACEUTICALS CORPORATION (US) | 2004-04-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (24 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210363134-A1 | NOVEL ANTHRANILAMIDES, THEIR USE AS INSECTICIDE AND PROCESSES FOR PREPARING THE SAME | DDT, CYP1A2, CYP1A1 | PLK4 3164/4885CHEK1 4321/4885AURKA 968/4885 |
| US-20060030613-A1 | Indole, indazole and indoline derivatives as CETP inhibitors | CETP, NAT1, MTTP | PLK4 2164/4885CHEK1 2085/4885AURKA 1502/4885 |
| US-10174005-B2 | Fused pyrimidines as inhibitors of p97 complex | WDR77, POP1, PSMG3 | PLK4 1845/4885CHEK1 1783/4885AURKA 935/4885 |
| US-12221436-B2 | Anthranilamides, their use as insecticide and processes for preparing the same | CYP1A2, ANTXR2, DDT | PLK4 3363/4885CHEK1 4519/4885AURKA 1074/4885 |
| US-20080167345-A1 | Anticancer, antiinflammatory, antitumor agents, diabetes, neurodegenerative diseases, retroviral infection, retinal damage or skin senescence and UV-induced skin damage; protecting against the toxicity of chemotherapy; 2-(4-Piperidin-3-ylphenyl)2H-indazole-7-carboxamide | PARP1, PARP2, PARP11 | PLK4 347/4885CHEK1 57/4885AURKA 1506/4885 |
| US-20090275619-A1 | Amide Substituted Indazole and Benzotriazole Derivatives as Poly(ADP-Ribose)Polymerase (PARP) Inhibitors | PARP1, PARP3, PARP2 | PLK4 309/4885CHEK1 43/4885AURKA 804/4885 |
| US-20240417407-A1 | FUROINDAZOLE DERIVATIVES AS GPR84 ANTAGONISTS | GPR84, GPR88, GPR65 | PLK4 871/4885CHEK1 2717/4885AURKA 2088/4885 |
| US-20180044325-A1 | FUSED PYRIMIDINES AS INHIBITORS OF P97 COMPLEX | WDR77, POP1, PSMG3 | PLK4 1822/4885CHEK1 1762/4885AURKA 892/4885 |
| US-11649255-B2 | Indazoles as hematopoietic progenitor kinase 1 (HPK1) inhibitors and methods using same | IP6K1, HIPK1, IP6K3 | PLK4 185/4885CHEK1 179/4885AURKA 389/4885 |
| US-20110201657-A1 | AMIDE SUBSTITUTED INDAZOLE AND BENZOTRIAZOLE DERIVATIVES AS POLY(ADP-RIBOSE)POLYMERASE (PARP) INHIBITORS | PARP1, PARP3, PARP2 | PLK4 309/4885CHEK1 43/4885AURKA 804/4885 |
| US-11535621-B2 | Heterobicyclic amides as inhibitors of CD38 | CD38, PARP12, ENTPD2 | PLK4 2927/4885CHEK1 715/4885AURKA 446/4885 |
| US-20220098193-A1 | INDAZOLES AS HEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) INHIBITORS AND METHODS USING SAME | IP6K1, HIPK1, IP6K3 | PLK4 185/4885CHEK1 179/4885AURKA 389/4885 |
| US-20230112499-A1 | FUROINDAZOLE DERIVATIVES | PKD1, CYP11B1, PKD2 | PLK4 1257/4885CHEK1 2769/4885AURKA 3383/4885 |
| US-20150299167-A1 | Regioselective N-2 Arylation of Indazoles | PARP2, PARP1, PARP12 | PLK4 1557/4885CHEK1 73/4885AURKA 446/4885 |
| US-20240383905-A1 | FGFR INHIBITORS AND METHODS OF USE THEREOF | FGFR1, FGFR3, FGFR4 | PLK4 790/4885CHEK1 840/4885AURKA 210/4885 |
| US-20170137403-A1 | REGIOSELECTIVE N-2 ARYLATION OF INDAZOLES | PARP2, PARP1, PARP12 | PLK4 1557/4885CHEK1 73/4885AURKA 446/4885 |
| US-12570666-B2 | Furoindazole derivatives | FURIN, CYP2F1, CYP3A7 | PLK4 3730/4885CHEK1 2122/4885AURKA 3913/4885 |
| US-20220267306-A1 | HETEROCYCLIC PROLINAMIDE DERIVATIVES | HTRA1, ALDH1A2, HTRA2 | PLK4 3022/4885CHEK1 4155/4885AURKA 4314/4885 |
| US-10435386-B2 | Regioselective N-2 arylation of indazoles | PARP2, PARP1, PARP12 | PLK4 1557/4885CHEK1 73/4885AURKA 446/4885 |
| US-20070185182-A1 | Heteroaryl carboxamide compounds | ABCB1, ABCG2, CYP3A43 | PLK4 3927/4885CHEK1 3488/4885AURKA 1576/4885 |
| US-10815214-B2 | Regioselective N-2 arylation of indazoles | PARP2, PARP1, PARP12 | PLK4 1557/4885CHEK1 73/4885AURKA 446/4885 |
| US-11377439-B2 | Heterocyclic prolinamide derivatives | HTRA1, ALDH1A2, HTRA2 | PLK4 2937/4885CHEK1 4174/4885AURKA 4229/4885 |
| US-20250270212-A1 | CHIMERIC COMPOUNDS USEFUL IN TREATING DISEASES | WEE1, WEE2, PARP1 | PLK4 1323/4885CHEK1 798/4885AURKA 1686/4885 |
| US-20240239804-A1 | FUROINDAZOLE DERIVATIVES AS ANTAGONISTS OR INHIBITORS OF GPR84 | GPR84, GPR88, FFAR1 | PLK4 1003/4885CHEK1 2913/4885AURKA 1961/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.